Search Results - "Schutz, F A B"

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes by Schutz, F.A.B., Je, Y., Azzi, G.R., Nguyen, P.L., Choueiri, T.K.

“…Bevacizumab, a humanized monoclonal antibody targeting the vascular endothelial growth factor, is a therapeutic agent used in a variety of neoplasms. We did a…”
Get full text

Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls by Bellmunt, J., Choueiri, T.K., Schutz, F.A.B., Rosenberg, J.E.

Get full text

858PRisk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents: A meta-analysis of randomized controlled trials by Mariano, R Coutinho, Gomes, L M, Oliveira, C, Galdino, A C, Araújo, J A P, Vargas, D, Maluf, F C, De Velasco Oria de Rueda, G A, Schutz, F A B

“…Abstract Background New hormonal agents (NHA) have been widely used to treat patients with metastatic and non-metastatic CRPC, with abiraterone, enzalutamide…”
Get full text

LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E, Galsky, M, Arranz Arija, J A, De Santis, M, Davis, I D, De Giorgi, U F F, Mencinger, M, Kikuchi, E, Garcia del Muro, X, Gumus, M, Özgüroğlu, M, Rezazadeh Kalebasty, A, Park, S H, Alekseev, B Y, Schutz, F A B, Li, J-R, Mecke, A, Mariathasan, S, Thastrom, A, Bamias, A

“…Abstract Background First-line (1L) mUC treatment (tx) includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending…”
Get full text

Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome by Dabydeen, D. A., Jagannathan, J. P., Ramaiya, N. H., Krajewski, K. M., Schutz, F. A. B., Cho, D. C., Pedrosa, I., Choueiri, T. K.

“…Abstract only…”
Get full text

Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine by Krajewski, K. M., Fougeray, R., Choueiri, T. K., Pons, F., Schutz, F. A. B., Rosenberg, J. E., Salhi, Y., Bellmunt, J.

“…Abstract only…”
Get full text

Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study by Schutz, F. A. B., Gray, K. P., Pomerantz, M., Atkins, M. B., Rosenberg, J. E., Hirsch, M. S., McDermott, D. F., Lee, G. M., Signoretti, S., Kantoff, P. W., Freedman, M. L., Choueiri, T. K.

“…Abstract only…”
Get full text

Identification of ALK gene alterations in urothelial carcinoma (UC) by Bellmunt, J., Selvarajah, S., Rodig, S., Salido, M., Costa, I., Bellosillo, B., Werner, L., Namgyal, C., Schutz, F. A. B., Pons, F., O'Brien, R., Barretina, J., Signoretti, S., Loda, M., Albanell, J., Choueiri, T. K., Berman, D. M., Kantoff, P. W., Rosenberg, J. E.

“…Abstract only…”
Get full text

Identification of a novel urothelial carcinoma (UC) biomarker of lethality by Rosenberg, J. E., Werner, L., Selvarajah, S., Weir, B., Regan, M. M., Jacobus, S. J., Berman, D. M., Schutz, F. A. B., O'Brien, R., Choueiri, T. K., Barretina, J., Signoretti, S., Loda, M., Guancial, E. A., Gallardo, E., Rojo, F. G., Lloreta, J., Hahn, W. C., Kantoff, P. W., Bellmunt, J.

“…Abstract only…”
Get full text